Pompe Disease Drug Discovery Service

Creative Biolabs provides Pompe disease drug discovery services for programs that need to restore acid alpha glucosidase activity, reduce lysosomal glycogen, improve enzyme delivery or processing, correct GAA variants, modulate secondary lysosomal and autophagy defects, or demonstrate functional rescue in skeletal, respiratory, cardiac, or neuromuscular models.

Support can include assay and model strategy, recombinant enzyme characterization, patient derived or engineered cell models, differentiated muscle systems, three dimensional tissues, compound or genetic screening, mechanism studies, biomarker development, animal efficacy, biodistribution, PK and PD alignment, tissue analysis, and integrated reporting.

Define the Pompe Disease Discovery Decision

Pompe disease is caused by deficient lysosomal acid alpha glucosidase, but a successful discovery program usually needs to resolve more than enzyme activity. A candidate may increase catalytic activity without reaching the lysosome, clear glycogen without correcting autophagic buildup, improve a cell marker without restoring muscle function, or perform differently across genotypes and disease stages.

Typical program questions include:

• Enzyme replacement optimization: Determine whether a recombinant GAA construct retains catalytic activity, remains stable, enters relevant cells, traffics to lysosomes, undergoes productive processing, and clears glycogen at a feasible exposure.
• Small molecule discovery: Identify stabilizers, pharmacological chaperones, trafficking enhancers, autophagy or lysosome modulators, glycogen pathway modifiers, or combination partners that produce a measurable disease relevant rescue.
• Gene and nucleic acid therapy: Compare vectors, promoters, payloads, mRNA or editing strategies for expression, secretion, uptake or cross correction, tissue distribution, durability, and functional consequence.
• Disease mechanism and biomarker work: Connect GAA deficiency and glycogen storage with lysosome expansion, impaired autophagic handling, metabolic stress, muscle pathology, neuronal involvement, and treatment responsive molecular signatures.
• Lead differentiation and translation: Rank candidates using orthogonal readouts, donor or genotype breadth, exposure response, target tissue delivery, tolerability, and biochemical as well as functional endpoints.

A Pompe program can be integrated with the broader Neuromuscular Disorders Drug Discovery Services or Rare Diseases Drug Discovery Services. Protein based programs can connect with Protein Dependent Neurological Disease Solutions, while vector and genome focused studies can connect with Gene Dependent Neurological Disease Solutions.

Build a Fit for Purpose Pompe Disease Model Portfolio

A cell free assay is efficient for catalytic ranking but cannot establish cellular uptake. A myoblast or myotube model can measure lysosomal storage and pathway responses but may not reproduce mature contractile behavior. Three dimensional muscle systems add architecture, longer culture windows, and functional testing. In vivo models provide systemic distribution, immune context, respiratory and cardiac physiology, and multi tissue exposure, yet the chosen genotype and age must match the disease claim.

Human Cells and Engineered Isogenic Models

Patient derived fibroblasts, myoblasts, or induced pluripotent stem cells can preserve clinically relevant GAA variants and modifier background. Custom Disease and Control iPSC Generation can support selected patient and control backgrounds, while Custom iPSC Differentiation can be used to generate project appropriate muscle, cardiac, neural, or other lineages when feasible. CRISPR engineered correction or introduction of a GAA variant can create isogenic comparisons that strengthen causal interpretation.

Three Dimensional and Neuromuscular Systems

Three dimensional skeletal muscle tissues can support longer exposure, myofiber organization, metabolic challenge, and force based endpoints. Neuromuscular systems can add motor neuron and muscle interaction when denervation, neuromuscular junction integrity, or neuronal GAA deficiency is relevant to the program.

Programs requiring multicellular neuromuscular context can also consider the Neuromuscular Organoid Modeling Service.

Mouse Models for Infantile and Late Onset Questions

GAA knockout and knock in models differ in residual activity, tissue pathology, cardiac involvement, timing of weakness, immune response, and relevance to a specific patient genotype. The study design therefore specifies whether the goal is broad loss of GAA function, a variant specific mechanism, early severe disease, later skeletal muscle progression, or evaluation of treatment after pathology is established. Age at dosing and readout is treated as a biological variable because glycogen burden, autophagic accumulation, muscle damage, and reversibility change over time. Sex, background strain, immune competence, prior treatment, and the expected human exposure are also considered.

Match the Screening Cascade to the Therapeutic Modality

The same assay sequence should not be applied to an enzyme, a small molecule, and a gene therapy vector. Each modality has a different proximal event, delivery constraint, time course, and failure mode. The discovery cascade begins with a sensitive measurement of the intended action, then adds cellular relevance, orthogonal confirmation, disease substrate reduction, pathway rescue, and function.

Recombinant Enzyme and Protein Engineering

For ERT focused programs, early assays can rank catalytic activity, stability, aggregation or degradation risk, receptor relevant binding, uptake, lysosomal trafficking, proteolytic maturation, and glycogen clearance. A candidate that performs well in a biochemical assay is retested in disease relevant human cells because glycosylation, mannose 6 phosphate content, uptake machinery, and intracellular processing can change activity. Lead comparison can also include persistence after washout, activity across donor or genotype backgrounds, response in mature muscle models, and the relationship between extracellular dose, intracellular enzyme, and substrate clearance.

Small Molecules and Combination Strategies

Small molecule studies may target residual mutant GAA stability, folding or trafficking, lysosome function, autophagic handling, glycogen metabolism, receptor mediated uptake, muscle stress pathways, or another validated modifier. Primary hits are confirmed from fresh material across a concentration range and are tested in healthy or corrected cells to identify nonspecific effects. Combination designs establish single agent ranges first and then test sequence, fixed ratio, or matrix conditions with a prespecified additivity or synergy method. A combination is advanced only when the gain is reproducible and not explained by cytotoxicity or assay compression.

Gene Therapy RNA and Genome Editing

Genetic programs may compare vector capsids, promoters, regulatory elements, codon or signal sequence variants, secreted or cell retained GAA designs, mRNA, gene editing, or other payload strategies. Early studies measure expression, functional enzyme, secretion where intended, uptake or cross correction, lysosomal localization, glycogen response, and durability. Later tiers address target tissue delivery, biodistribution, dose response, immune context, off target or unintended expression questions appropriate to the technology, and functional outcome. The study distinguishes production of GAA from delivery of active enzyme to the relevant lysosomal compartment.

Vector programs can draw on the Pre Made AAV Center for catalog exploration and can use the High Throughput Screening Platform when assay robustness, plate format, library size, and readout automation support a scaled screen. Screening scale is selected only after the disease phenotype and positive control window are reproducible.

Connect In Vitro Activity with In Vivo Exposure and Function

In vivo studies are designed to answer a defined translational question rather than repeat every cell based observation. The selected GAA deficient model, age, disease stage, dose route, treatment frequency, study duration, comparator, and tissues must match the proposed use of the candidate. For enzyme and protein therapies, tissue uptake and mature enzyme activity are central. For small molecules, systemic and muscle exposure must support the active range. For vectors or nucleic acids, expression, biodistribution, durability, and tissue selectivity are aligned with the pharmacodynamic schedule.

Representative in vivo support can include:

• Study design and execution: Randomized allocation, coded formulations, blinded data collection or analysis where feasible, baseline balancing, predefined exclusions, and animal welfare monitoring under the applicable approval.
• Tissue pharmacodynamics: GAA activity, glycogen content, PAS staining, LAMP and autophagy markers, vector genomes or expression where relevant, and region or muscle specific molecular measurements.
• Functional efficacy: Project selected strength, motor, respiratory, diaphragm, cardiac, endurance, or longitudinal activity endpoints interpreted in the context of age and disease severity.
• Exposure and distribution: Plasma and tissue concentration, brain or muscle exposure when applicable, biodistribution, pharmacokinetics, and the relationship between achieved exposure and response.
• Safety and immune context: Clinical observations, body weight, clinical pathology, tissue findings, anti drug or anti transgene response when within scope, and modality specific tolerability measures.

Exposure, formulation, stability, permeability, metabolism, and related developability questions can be coordinated with ADME and DMPK Services. Tissue changes can be evaluated through Brain Neurohistology Assays and project appropriate peripheral tissue histology, while sample based measurements can connect with Neural Biological Materials Biomarker Assays when the neurological or neuromuscular component is relevant. The final interpretation identifies whether the target tissue received enough active agent to test the hypothesis.

Related Research

The two studies show why Pompe disease drug discovery benefits from human functional muscle models and genotype defined in vivo systems, and why glycogen clearance should be interpreted alongside lysosomal, autophagy, tissue, and functional endpoints.

Human Three Dimensional Muscle Separates Biochemical Rescue from Functional Rescue

Wang and colleagues developed three dimensional skeletal muscle myobundles from individuals with infantile onset Pompe disease. The tissues showed reduced GAA activity, increased glycogen and lysosome abundance, and greater functional sensitivity to metabolic stress. Recombinant human GAA increased intracellular enzyme activity and reduced glycogen by approximately 77 percent, yet did not significantly normalize the tested lysosomal and autophagy markers or improve contractile deficits within the study window. AAV mediated GAA expression likewise restored activity and reduced glycogen without producing a parallel functional rescue.

Fig. 1 Response of infantile onset Pompe disease myobundles to recombinant human GAA treatment.^1,3

A Variant Specific Knock In Mouse Provides Tissue and Neurological Readouts

Kan and colleagues generated a CRISPR engineered mouse carrying the Gaa c.1935C>A variant associated with infantile onset Pompe disease. Homozygous mice had near absent GAA activity, increased glycogen in cardiac and skeletal muscle, impaired autophagy, muscle weakness, and cardiac hypertrophy. PAS staining demonstrated muscle glycogen storage, while increased LAMP1 immunoreactivity was observed in selected brain regions. The model illustrates how a genotype specific system can connect molecular correction to muscle, cardiac, and neurological tissue endpoints.

Fig. 2 Muscle glycogen storage and brain lysosomal abnormalities in Gaa c.1935C>A knock in mice.^2,3

Frequently Asked Questions

1. What is included in the Pompe Disease Drug Discovery Service?

   The service can include discovery strategy, biochemical and cellular GAA assays, patient derived or engineered models, muscle differentiation and three dimensional tissues, compound or genetic screening, hit confirmation, mechanism studies, animal efficacy, PK and PD, tissue analysis, biomarker work, statistics, and reporting. The final scope is selected around the therapeutic modality and project decision.

2. Which Pompe disease models can be used?

   Programs may use biochemical systems, patient derived fibroblasts or muscle cells, engineered cell lines, iPSC derived lineages, isogenic pairs, two dimensional myotubes, three dimensional muscle tissues, neuromuscular models, and GAA deficient knockout or variant specific knock in animals. Model availability and suitability depend on the genotype, disease stage, endpoint, and modality.

3. Which endpoints are most important for Pompe disease screening?

   Common anchor endpoints include functional GAA activity and glycogen reduction. Supporting measurements can assess cellular uptake, lysosomal localization, enzyme processing, LAMP proteins, lysosome burden, LC3 and p62, autophagic flux, morphology, viability, contractile force, fatigue, respiratory muscle function, cardiac measures, exposure, and biodistribution. The endpoint hierarchy is set before screening.

4. Can the service support enzyme replacement therapy development?

   Yes. Recombinant GAA candidates can be compared for catalytic activity, stability, uptake, lysosomal delivery, maturation, intracellular persistence, glycogen clearance, pathway rescue, and activity in disease relevant human or animal models. The study can distinguish biochemical potency from cellular delivery and functional efficacy.

5. Can small molecules or pharmacological chaperones be screened?

   Yes. Screening may evaluate mutant GAA stabilization, folding or trafficking, lysosomal and autophagy modulators, glycogen pathway targets, uptake enhancers, or combination partners. Hits are confirmed across concentrations with viability, healthy or corrected cell, assay interference, and mechanism appropriate countermeasures.

6. Can gene therapy and genome editing approaches be evaluated?

   Yes. Studies can compare vectors, capsids, promoters, payload designs, secreted or cell retained GAA, mRNA, or editing strategies. Readouts may include expression, functional enzyme, secretion, uptake or cross correction, lysosomal localization, glycogen clearance, durability, biodistribution, tissue selectivity, and functional outcome, subject to project feasibility.

7. How is biochemical rescue distinguished from functional rescue?

   The program uses an evidence ladder. GAA activity and glycogen clearance establish proximal correction, lysosomal and autophagy markers test downstream pathway rescue, and muscle, respiratory, cardiac, or neuromuscular endpoints test function. Exposure and time course data help determine why these layers may not improve in parallel.

8. Can infantile onset and late onset Pompe disease questions be studied separately?

   Yes. The model, genotype, residual activity, lineage, age, disease stage, treatment window, cardiac involvement, and functional endpoints can be selected to match an infantile or late onset question. Results from one model are not generalized to the full Pompe disease spectrum without supporting data.

9. What information is needed to plan a Pompe disease project?

   Helpful inputs include the therapeutic hypothesis, modality, target population or GAA variant, available test article, preferred model, prior activity or exposure data, primary endpoint, desired tissues, treatment window, sample requirements, timeline, and advancement criteria. If these are not fixed, the project can begin with a feasibility and assay strategy phase.

References

1. Wang, Jason, et al. "Three-Dimensional Tissue-Engineered Human Skeletal Muscle Model of Pompe Disease." Communications Biology, vol. 4, 2021, article 524. https://doi.org/10.1038/s42003-021-02059-4
2. Kan, Shih-Hsin, et al. "CRISPR-Mediated Generation and Characterization of a Gaa Homozygous c.1935C>A (p.D645E) Pompe Disease Knock-In Mouse Model Recapitulating Human Infantile-Onset Pompe Disease." Scientific Reports, vol. 12, 2022, article 21576. https://doi.org/10.1038/s41598-022-25914-8
3. Distributed under Open Access license CC BY 4.0, without modification.